Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 8956024

Experimental therapy.

S Charache
View original source ↗Export metadata ↓

Abstract

Bone marrow transplantation, hydroxyurea therapy in children and in patients with sickling disorders other than sickle cell anemia, and prophylactic transfusion for prevention of stroke in children are currently being evaluated as treatments for patients with sickle cell disease. Long-term complications of each of these treatments are incompletely understood. Attempts to inhibit sickling by lowering intracellular hemoglobin concentration are still in progress. Combinations of therapeutic agents with different modes of action, and development of more effective treatment schedules, may further improve the outlook of patients with sickling disorders.

Explore related subjects

Anemia, Sickle CellAntisickling AgentsBone Marrow TransplantationClinical Trials as TopicErythrocyte TransfusionHumansHydroxyureaJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Charache. 1996. Experimental therapy.. https://doi.org/10.1016/s0889-8588(05)70408-1

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Transgenic sickle mice have vascular inflammation.

Inflammation may play an essential role in vaso-occlusion in sickle cell disease. Sickle patients have high white counts and elevated levels of serum C-reactive protein (CRP), cytokines, and adhesion molecules. In addition, circulating endothelial cells, leukocytes, and platelets are activated. We examined 4 transgenic mouse models expressing human alpha- and sickle beta-globin genes to determine if they mimic the inflammatory response seen in patients. These mouse models are designated NY-S, Berk-S(Antilles), NY-S/S(Antilles) (NY-S x Berk-S(Antilles)), and Berk-S. The mean white counts were elevated 1.4- to 2.1-fold (P </=.01) in the Berk-S(Antilles), NY-S/S(Antilles), and Berk-S mice, but not in the NY-S mice compared with controls. Serum amyloid P-component (SAP), an acute-phase response protein with 60% to 70% sequence homology to CRP, was elevated 8.5- to 12.1-fold (P </=.001) in transgenic sickle mice. Similarly, serum interleukin-6 (IL-6) was elevated 1.6- to 1.9-fold (P </=.05). Western blots, confirming immunohistochemical staining, showed vascular cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), and platelet-endothelial cell adhesion molecule (PECAM) were up-regulated 3- to 5-fold (P </=.05) in the lungs of sickle mice. Ribonuclease protection assays (RPAs) demonstrated VCAM mRNA also was elevated in sickle mice 1.2- to 1.4-fold (P </=.01). Nuclear factor kappaB (NF-kappaB), a transcription factor critical for the inflammatory response, was elevated 1.9-fold (P </=.006) in NY-S sickle mouse lungs. We conclude that transgenic sickle mice are good models to study vascular inflammation and the potential benefit of anti-inflammatory therapies to prevent vaso-occlusion in sickle cell disease.

Anemia, Sickle Cell↗
PubMed2003

Interaction of sickle cell trait with hereditary spherocytosis: splenic infarcts and sequestration.

The association of sickle cell trait (SCT) and hereditary spherocytosis (HS) has been reported in only 18 patients. Three of these 18 patients experienced splenic infarct or acute splenic sequestration. We report here a 46-year-old African-American male, the oldest reported case to date, who experienced episodes of hemolysis and severe left upper quadrant pain for the past 26 years. The patient had compensated hemolysis with splenomegaly. A CT scan of the abdomen revealed a large infarct in the spleen. The diagnosis of SCT was confirmed with isoelectric focusing, cation exchange and reverse-phase HPLC. The presence of a silent, interacting globin variant as the cause of hemolysis and sickling in the spleen was ruled out by sequencing of the alpha1-, alpha2- and beta-globin genes. The diagnosis of HS was established by an osmotic fragility test. The interaction of HS and SCT leads to RBC dehydration with increased MCHC and intracellular Hb S concentration presumably favoring intrasplenic sickling and resultant splenic infarcts and sequestration as seen in this case.

Anemia, Sickle Cell↗